Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DR26FNL1R
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,449
Award facts
- Contract value 100% obligated
- $18,448.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $18,448.72 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen auto-injectors on October 21, 2025, with completion scheduled for October 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The delivery is being fulfilled under the company's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling supply of medications and medical commodities to military healthcare programs worldwide.
Dupixent (dupilumab) is a prescription biologic indicated for multiple allergic and inflammatory conditions including atopic dermatitis, asthma, and chronic rhinosinusitis. This procurement represents routine pharmaceutical fulfillment under the broader IDC framework, demonstrating AmerisourceBergen's ongoing role in maintaining medical supply chains for the Defense Health Agency and other federal healthcare systems. The DLA continues to leverage AmerisourceBergen's established capabilities as a prime pharmaceutical vendor, with the agency planning to expand pharmaceutical support through generation V contracts involving multiple regional awards among different contractors.
Quick answers
Who was awarded contract SPE2DR26FNL1R?
SPE2DR26FNL1R was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 21, 2025.
How much is contract SPE2DR26FNL1R worth?
The government has obligated $18,449 on SPE2DR26FNL1R.
Is contract SPE2DR26FNL1R an order under another contract?
Yes. SPE2DR26FNL1R is a delivery order under SPE2DR25D1021, an indefinite delivery contract.
Was contract SPE2DR26FNL1R competed?
The extent of competition for SPE2DR26FNL1R was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award